Featured news in The Life Sciences Report
|
|
|
Caladrius Biosciences Inc. (CLBS:NASDAQ) Caladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease (6/22/2021) |
|
view |